Screener / SEC EDGAR /CIK 0001393434 /10-K filed Feb 5, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Pharmaceuticals

Ocular Therapeutix, Inc OCUL

We are an integrated biopharmaceutical company committed to redefining the retina experience. 10-K, Item 1

Headquarters
Bedford, MA
CEO
Pravin Dugel
Next results
around Feb 4, 2027
Compare with peers Embed

OCUL among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: -18.5%, above 3% of 154 peers (their median 10.5%) REVENUE GROWTH -18.5% · above 3% Gross margin: 87.3%, above 92% of 107 peers (their median 63.4%) GROSS MARGIN 87.3% · above 92% Operating margin: -680.9%, above 1% of 138 peers (their median 10.2%) OPERATING MARGIN -680.9% · above 1% Net margin: -648.6%, above 3% of 153 peers (their median 6.8%) NET MARGIN -648.6% · above 3% FCF margin: -530.0%, above 1% of 144 peers (their median 10.1%) FCF MARGIN -530.0% · above 1%
OCUL Peer median Below the median

What changed

40 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 5, 2026 against Mar 3, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Inventory growing faster than revenue
    Inventory +17.2% ($3.0M to $3.6M) vs revenue -18.5% ($63.7M to $52.0M), +35.7 pts apart
  • Receivables -5.4% ($32.4M to $30.6M) vs revenue -18.5% ($63.7M to $52.0M), +13.1 pts apart
9 more checks with nothing to note
  • Cash from operations −$204.9M vs net income −$265.9M (FY ending Dec 31, 2025)
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Revenue Recognition - DEXTENZA
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

40 paragraphs in Risk Factors that were not in the 10-K filed Mar 3, 2025. Quoted as filed.

All 40 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
    Changes in tax laws or in their implementation or interpretation could adversely affect our business and financial condition. Income, sales, use or other tax laws, statutes, rules, or regulations could be enacted or amended at any time, which could affect our business or financial condition, including causing potentially adverse impacts…
  2. Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
    Additionally, although the FDA has indicated a general openness to requiring only one pivotal clinical trial for approval of a product candidate, the FDA has not yet provided specific guidance on how that approach is to be implemented. Our current plans call for the submission of an application for marketing approval of AXPAXLI for the…
  3. Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
    For example, following recent public statements from FDA leadership, pending the receipt of favorable topline results and planned interactions with the FDA, we intend to submit an NDA for AXPAXLI for the treatment of wet AMD based on Week 52 data from the SOL-1 trial. As the FDA has historically required two adequate and well-controlled…
  4. Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
    In December 2022, with the passage of FDORA, Congress required sponsors to develop and submit a diversity action plan, or DAP, for each phase 3 clinical trial or any other “pivotal study” of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$51.5M$58.4M$63.7M$52.0M
Net income−$71.0M−$80.7M−$193.5M−$265.9M
Operating cash flow−$59.6M−$70.2M−$134.7M−$204.9M
Free cash flow−$63.3M−$76.3M−$136.0M−$216.9M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$52.0M ▼ 18.5% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

4 filings in the last 30 days · SEC EDGAR

All filings

About the company

Ocular Therapeutix, Inc, Bedford, MA · from the 10-K filed Feb 5, 2026

We are an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI, also known as OTX-TKI, our investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on our ELUTYX proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently being evaluated in a Phase 3 registrational program for wet age-related macular degeneration, or wet AMD, which we refer to as the SOL program. AXPAXLI is currently also being evaluated in a Phase 3 registrational program for diabetic retinal disease, including non-proliferative diabetic retinopathy, or NPDR, which we refer to as the HELIOS program.

Headquarters
Bedford, MA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 9, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 5, 2026 (open at SEC), compared with the 10-K filed Mar 3, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/OCUL/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.